Eyebright Medical Technology Stock Fundamentals
| 688050 Stock | 90.61 1.90 2.05% |
Eyebright Medical Technology fundamentals help investors to digest information that contributes to Eyebright Medical's financial success or failures. It also enables traders to predict the movement of Eyebright Stock. The fundamental analysis module provides a way to measure Eyebright Medical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eyebright Medical stock.
At present, Eyebright Medical's Depreciation And Amortization is projected to increase significantly based on the last few years of reporting. The current year's Interest Expense is expected to grow to about 10.3 M, whereas Tax Provision is forecasted to decline to about 25.8 M. Eyebright | Select Account or Indicator |
Eyebright Medical Technology Company Current Valuation Analysis
Eyebright Medical's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Eyebright Medical Current Valuation | 16.91 B |
Most of Eyebright Medical's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eyebright Medical Technology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Eyebright Medical Technology has a Current Valuation of 16.91 B. This is 17.71% higher than that of the Health Care Equipment & Supplies sector and 84.92% higher than that of the Health Care industry. The current valuation for all China stocks is 1.7% lower than that of the firm.
Eyebright Medical Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eyebright Medical's current stock value. Our valuation model uses many indicators to compare Eyebright Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eyebright Medical competition to find correlations between indicators driving Eyebright Medical's intrinsic value. More Info.Eyebright Medical Technology is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.59 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Eyebright Medical Technology is roughly 1.69 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Eyebright Medical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Eyebright Medical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Eyebright Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eyebright Medical's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eyebright Medical could also be used in its relative valuation, which is a method of valuing Eyebright Medical by comparing valuation metrics of similar companies.Eyebright Medical is currently under evaluation in current valuation category among its peers.
Eyebright Fundamentals
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0872 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.33 % | ||||
| Current Valuation | 16.91 B | ||||
| Shares Outstanding | 189.54 M | ||||
| Shares Owned By Insiders | 38.48 % | ||||
| Shares Owned By Institutions | 20.78 % | ||||
| Price To Book | 7.20 X | ||||
| Price To Sales | 12.91 X | ||||
| Revenue | 951.18 M | ||||
| Gross Profit | 491.15 M | ||||
| EBITDA | 506.62 M | ||||
| Net Income | 304.43 M | ||||
| Total Debt | 117.94 M | ||||
| Book Value Per Share | 12.29 X | ||||
| Cash Flow From Operations | 212.62 M | ||||
| Earnings Per Share | 1.95 X | ||||
| Target Price | 115.8 | ||||
| Number Of Employees | 2.07 K | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 17.53 B | ||||
| Total Asset | 3.06 B | ||||
| Retained Earnings | 647.18 M | ||||
| Working Capital | 645.1 M | ||||
| Annual Yield | 0.01 % | ||||
| Net Asset | 3.06 B | ||||
| Last Dividend Paid | 0.27 |
About Eyebright Medical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eyebright Medical Technology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eyebright Medical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eyebright Medical Technology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Total Revenue | 951.2 M | 998.7 M | |
| Cost Of Revenue | 228.2 M | 239.6 M |
Currently Active Assets on Macroaxis
Other Information on Investing in Eyebright Stock
Eyebright Medical financial ratios help investors to determine whether Eyebright Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Eyebright with respect to the benefits of owning Eyebright Medical security.